Clinical Trial Update: Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus [Phase 2]

View source ↗

Summary

A Phase 2 placebo-controlled study to evaluate the safety and efficacy of lanifibranor alone and in combination with empagliflozin in patients with nonalcoholic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis
• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)
• Lanifibranor (lanifibranor)

Snippet

Sponsor: Inventiva Pharma | Conditions: NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED